Literature DB >> 31073686

In Vivo-Relevant Transwell Dish-Based Dissolution Testing for Orally Inhaled Corticosteroid Products.

Masahiro Sakagami1, Hua Li2, Jügen Venitz2.   

Abstract

PURPOSE: To establish an in vivo-relevant Transwell dish-based dissolution test system for the "respirable" aerosols of inhaled corticosteroids (ICSs) using marketed inhaler products.
METHODS: "Respirable" ≤ 5.8 or 6.5 μm aerosols of 7 ICSs from 11 inhaler products were collected onto the filter membranes under the modified assembly of the cascade impactor. Their dissolution in 10 ml of the simulated lung lining fluid (sLLF) was determined over time in the Transwell dish at 37°C and ~100% relative humidity in the presence of subsequent diffusive permeation across the Transwell's supporting membrane.
RESULTS: While three ICSs with high-to-intermediate solubility enabled the first-order "sink" and complete dissolution in 6 h, 4 ICSs with poor solubility including fluticasone propionate (FP) resulted in the pseudo-zero-order "non-sink", slow and limited dissolution. The aerosol dissolution rate constants (kdiss) were derived, well-correlated with the solubility. For FP, but not for highly-soluble flunisolide (FN), dissolution was kinetically aerosol mass-dependent. However, for a given ICS, dissolution profiles were indistinguishable between the formulations and products upon comparable aerosol mass collection.
CONCLUSIONS: The in vivo-relevant Transwell dish-based "respirable" aerosol dissolution test system was developed, kinetically discriminative in accordance with the ICS solubility, but indistinguishable for a given ICS between the marketed products.

Entities:  

Keywords:  bioequivalence; cascade impactor; dissolution; inhaled corticosteroid; transwell

Mesh:

Substances:

Year:  2019        PMID: 31073686     DOI: 10.1007/s11095-019-2635-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling.

Authors:  S Krishnaswami; G Hochhaus; H Möllmann; J Barth; H Derendorf
Journal:  Int J Clin Pharmacol Ther       Date:  2005-03       Impact factor: 1.366

2.  The abbreviated impactor measurement (AIM) concept: part 1--Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

3.  Development of a standardized dissolution test method for inhaled pharmaceutical formulations.

Authors:  Yoen-Ju Son; Jason T McConville
Journal:  Int J Pharm       Date:  2009-08-07       Impact factor: 5.875

4.  Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.

Authors:  Wallace P Adams; Richard C Ahrens; Mei-Ling Chen; David Christopher; Badrul A Chowdhury; Dale P Conner; Richard Dalby; Kevin Fitzgerald; Leslie Hendeles; Anthony J Hickey; Günther Hochhaus; Beth L Laube; Paul Lucas; Sau L Lee; Svetlana Lyapustina; Bing Li; Dennis O'Connor; Neil Parikh; David A Parkins; Prasad Peri; Gary R Pitcairn; Michael Riebe; Partha Roy; Tushar Shah; Gur Jai Pal Singh; Sandra Suarez Sharp; Julie D Suman; Marjolein Weda; Janet Woodcock; Lawrence Yu
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-02       Impact factor: 2.849

5.  Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report.

Authors:  Dennis O'Connor; Wallace P Adams; Mei-Ling Chen; Peter Daley-Yates; John Davis; Hartmut Derendorf; Murray P Ducharme; Anders Fuglsang; Myra Herrle; Günther Hochhaus; Susan M Holmes; Sau L Lee; Bing V Li; Svetlana Lyapustina; Stephen Newman; Martin Oliver; Beverley Patterson; Joanne Peart; Guirag Poochikian; Partha Roy; Tushar Shah; Gur Jai Pal Singh; Sandra Suarez Sharp
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-03-31       Impact factor: 2.849

Review 6.  In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.

Authors:  Ben Forbes; Per Bäckman; David Christopher; Myrna Dolovich; Bing V Li; Beth Morgan
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

Review 7.  International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences.

Authors:  Dongmei Lu; Sau L Lee; Robert A Lionberger; Stephanie Choi; Wallace Adams; Hoainhon N Caramenico; Badrul A Chowdhury; Dale P Conner; Rohit Katial; Susan Limb; John R Peters; Lawrence Yu; Sally Seymour; Bing V Li
Journal:  AAPS J       Date:  2015-03-11       Impact factor: 4.009

Review 8.  Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs).

Authors:  Trevor Riley; David Christopher; Jan Arp; Andrea Casazza; Agnes Colombani; Andrew Cooper; Monisha Dey; Janet Maas; Jolyon Mitchell; Maria Reiners; Nastaran Sigari; Terrence Tougas; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2012-07-14       Impact factor: 3.246

Review 9.  Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives.

Authors:  Gabriela Apiou-Sbirlea; Steve Newman; John Fleming; Ruediger Siekmeier; Stephan Ehrmann; Gerhard Scheuch; Guenther Hochhaus; Anthony Hickey
Journal:  Ther Deliv       Date:  2013-03

10.  In vitro aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products.

Authors:  Deepika Arora; Kumar A Shah; Matthew S Halquist; Masahiro Sakagami
Journal:  Pharm Res       Date:  2010-03-13       Impact factor: 4.200

View more
  2 in total

1.  What makes flunisolide different among inhaled corticosteroids used for nebulization: a close look at the role of aqueous solubility.

Authors:  Ahmad Kantar
Journal:  Multidiscip Respir Med       Date:  2021-01-15

2.  Model for the Analysis of Membrane-Type Dissolution Tests for Inhaled Drugs.

Authors:  Göran Frenning; Irès van der Zwaan; Frans Franek; Rebecca Fransson; Ulrika Tehler
Journal:  Mol Pharm       Date:  2020-06-15       Impact factor: 4.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.